Format

Send to

Choose Destination
Nat Rev Genet. 2014 Jul;15(7):445-51. doi: 10.1038/nrg3742. Epub 2014 May 20.

Engineering adeno-associated viruses for clinical gene therapy.

Author information

1
Department of Chemical and Biomolecular Engineering, University of California, Berkeley, California 94720-3220, USA.
2
1] Department of Chemical and Biomolecular Engineering, University of California, Berkeley, California 94720-3220, USA. [2] Department of Bioengineering, and the Department of Molecular and Cell Biology, University of California, Berkeley, California 94720-3220, USA.

Abstract

Clinical gene therapy has been increasingly successful owing both to an enhanced molecular understanding of human disease and to progressively improving gene delivery technologies. Among these technologies, delivery vectors based on adeno-associated viruses (AAVs) have emerged as safe and effective and, in one recent case, have led to regulatory approval. Although shortcomings in viral vector properties will render extension of such successes to many other human diseases challenging, new approaches to engineer and improve AAV vectors and their genetic cargo are increasingly helping to overcome these barriers.

PMID:
24840552
PMCID:
PMC4393649
DOI:
10.1038/nrg3742
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center